Status:
ACTIVE_NOT_RECRUITING
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Lead Sponsor:
Pfizer
Conditions:
Hemophilia A or B
Eligibility:
All Genders
Brief Summary
A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.
Detailed Description
The objective of this study is to assess the safety of this drug under actual usage conditions in patients with congenital hemophilia who do not have inhibitors. The observation period will be up to ...
Eligibility Criteria
Inclusion
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Patients who have received at least one dose of this drug after the launch of this drug
Exclusion
Key Trial Info
Start Date :
October 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 13 2029
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07161687
Start Date
October 30 2025
End Date
December 13 2029
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer, Inc
Tokyo, Japan